Annual Information Update





RNS Number : 1385Q
Oxford Biomedica PLC
03 April 2009
 



For Immediate Release

3 April 2009

Oxford BioMedica plc ("Oxford BioMedica" or the "Company")

Annual Information Update for the Twelve Months to 3 April 2009

Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority. 

1.     Announcements made via a Regulatory Information Service

Date  

Announcement

15 April 2008

Notice of changes in board composition to be effective July 2008

30 April 2008

Total voting rights update

9 May 2008

Interim management statement

9 May 2008

Annual general meeting statement

16 May 2008

Notice of TroVax clinical data presentation

19 May 2008

Corporate presentation at Rodman & Renshaw healthcare conference

27 May 2008

Corporate presentation at FBR capital markets conference

30 May 2008

Total voting rights update

30 May 2008

Blocklisting interim review

2 June 2008

TroVax clinical data presentation

24 June 2008

Corporate presentation at Jefferies healthcare conference

1 July 2008

Board changes: retirement of Chairman and Chief Scientific Officer, appointment of new Chief Scientific Officer, changes to roles of three directors

1 July 2008

Response to Bavarian Nordic US patent infringement action

11 July 2008

Update on TroVax phase III clinical trial in renal cancer

14 July 2008

Update on planned TroVax clinical trial in colorectal cancer

15 July 2008

Further update on TroVax phase III clinical trial in renal cancer

28 July 2008

Board change: appointment of non-executive director

15 August 2008

Rejection of indicative approach by GeneThera Inc.

15 August 2008

Rule 2.10 announcement

18 August 2008

Holding(s) in Company

27 August 2008

Notice of interim results

29 August 2008

Interim results

29 August 2008

Board change: resignation of CEO, acting CEO appointed

9 September 2008

ProSavin clinical data

10 September 2008

Directors' interests in shares 

18 September 2008

Corporate presentation at UBS life sciences conference

7 October 2008

Update on TroVax phase III clinical trial in renal cancer

13 October 2008

Board change: permanent CEO confirmed

14 October 2008

Holding(s) in Company

24 October 2008

TroVax clinical data presentation

7 November 2008

Corporate presentation at Rodman & Renshaw healthcare conference

14 November 2008

Presentation of ProSavin clinical data 

18 November 2008

Interim management statement

19 November 2008

ProSavin clinical data

28 November 2008

Blocklisting interim review

12 January 2009

Dismissal of Bavarian Nordic US patent infringement action

27 January 2009

Response to re-filed US patent infringement action

5 February 2009

Issue of shares re. investment in StarGen development

25 February 2009

Notice of results 

27 February 2009

Total voting rights update

4 March 2009

Holding(s) in Company

10 March 2009

Holding(s) in Company

12 March 2009

Preliminary results for 2008

20 March 2009

Holding(s) in Company

23 March 2009

Holding(s) in Company

25 March 2009

Directors' interests in shares and share options

31 March 2009

Annual report & accounts and AGM notification

3 April 2009

Annual information update

Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at www.londonstockexchange.com  and on the Oxford BioMedica website at http://www.oxfordbiomedica.co.uk  

2. Documents filed with Companies House

Date  

Document Type  

Description

 

 

21 May 2008

AGM Special Business

AGM minutes

1 July 2008

288b Resignation of a director

Dr Peter Johnson

1 July 2008

288b Resignation of a director

Dr Susan Kingsman

1 July 2008

288a Appointment of director

Dr Stuart Naylor

1 August 2008

288a Appointment of director

John Dawson

28 August 2008

288b Resignation of a director

Dr Michael McDonald

20 September 2008

363s Annual Return

Annual return

11 February 2009

88(2) Return of Allotment of shares

Allotment 215,445 1p Ord.

11 February 2009

88(2) Return of Allotment of shares

Allotment 2,209,042 1p Ord.

Copies of documents filed at Companies House can be obtained from Companies House, Crown WayCardiff CF14 3UZ or through Companies House Direct at www.direct.companieshouse.gov.uk  

3. Documents published or sent to shareholders or filed with the UKLA Viewing Facility

Date  

Description

16 September 2008

Interim Report for 6 months to 30 June 2008

31 March 2009

Annual report for the year ended 31 December 2008

Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office: 

This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person. 

Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park

Oxford 

OX4 4GA

3 April 2009


This information is provided by RNS
The company news service from the London Stock Exchange
 

END

 
 

AIUEXLFBKZBBBBE